

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 July 2022 (21.07.2022)



(10) International Publication Number
WO 2022/152109 A2

(51) International Patent Classification:

C07C 217/08 (2006.01) C07C 229/30 (2006.01)
C07F 9/24 (2006.01) C07C 233/36 (2006.01)
A61K 9/127 (2006.01) C07C 237/06 (2006.01)
A61K 9/51 (2006.01) C07C 271/12 (2006.01)
A61K 31/7105 (2006.01) C07C 271/20 (2006.01)
A61K 47/18 (2017.01) C07C 211/58 (2006.01)
C07C 219/06 (2006.01) C07F 9/22 (2006.01)
C07C 219/14 (2006.01) C07C 229/14 (2006.01)
C07C 229/24 (2006.01) C07D 211/58 (2006.01)

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/CN2022/071251

(22) International Filing Date:

11 January 2022 (11.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202110051373.1 14 January 2021 (14.01.2021) CN
63/140,691 22 January 2021 (22.01.2021) US
PCT/CN2021/122704
08 October 2021 (08.10.2021) CN

(71) Applicant: **SUZHOU ABOGEN BIOSCIENCES CO., LTD.** [CN/CN]; B1-501, 218 Xinghu Ave, Biobay, Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN).

(72) Inventors: **YING, Bo**; B1-501, 218 Xinghu Ave, Biobay, Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN).
WANG, Xiulian; B1-501, 218 Xinghu Ave, Biobay, Suzhou Industrial Park, Suzhou, Jiangsu 215123 (CN).

(74) Agent: **CHINA PATENT AGENT (H.K.) LTD.**; 22/F., Great Eagle Center, 23 Harbour Road, Wanchai, Hong Kong (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS

(57) Abstract: Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination. Also provided herein are lipid nanoparticle compositions comprising said lipid compounds.

WO 2022/152109 A2